Stocks · News reference
Anavex Life Sciences Regains Nasdaq Compliance
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system ("CNS")
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Anavex Life Sciences Receives FDA Clearance to Proceed Ahead With Its Planned Clinical Trial Under Its Investigational New Drug Application For ANAVEX 2-73 For Fragile X Syndrome
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corp. (AVXL)
A securities class action lawsuit has been filed against Anavex Life Sciences Corp. (AVXL) for allegedly failing to disclose inadequate internal controls and regulatory challenges stemming from former CEO misconduct. The lawsuit covers securities purchased between November 26, 2025 and August 28, 2026. Investors have until November 30, 2026 to file as lead plaintiffs.
8-K filing — ANAVEX LIFE SCIENCES CORP. (AVXL)
Filed: 2026-09-28 AccNo: 0001731122-26-001294 Size: 206 KB Item 5.01: Changes in Control of Registrant Item 5.07: Submission of Matters to a Vote of Security Holders